TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy1,2
|
Improving Outcomes Overall
Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision using the Oncotype DX test to identify:
- the vast majority of patients with no chemotherapy benefit
- the important minority for whom chemotherapy may be life-saving
|
TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit1,2
|
73%
of patients with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**
*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
**Based on the primary analysis of TAILORx study
43%
of patients with Recurrence Score results 26-100 had low clinical risk*** and may have been undertreated without the Recurrence Score result
***Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.